Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.125p +1.00% 12.625p 12.25p 13.00p 13.00p 13.00p 13.00p 66,592 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 66.46

Vernalis Share Discussion Threads

Showing 3401 to 3425 of 3425 messages
Chat Pages: 137  136  135  134  133  132  131  130  129  128  127  126  Older
DateSubjectAuthorDiscuss
14/11/2017
11:20
desperately in need of some positive news here to reverse the slump
bountyhunter
14/11/2017
10:43
So you sold out and someone else kweeps buying. Good move.
hvs
30/10/2017
12:06
I recently reduced my holding here by over 60% as the opportunity arose to swap out the funds into Shire, with its share price severely down for no good reason it makes a lot of sense to do so - far more certainty of a recovery and profits at Shire than here. And CEO Flemming O is leagues ahead of this no hoper Ian Garland at Vernalis. Looks very much like Vernalis strategy is hostage to its partner Tris, with no control over what looks like an increasingly chaotic situation. Can only hope Vernalis is applying pressure but months on and still no word of progress. Strategy making less and less sense with ongoing cash burn at $20m but revenues just a few million, how can this ever make sense without more products hitting the market in a reasonable time.
romeike
27/10/2017
22:01
First post but thought this glassdoor review might give you a little insight in to tri pharma. Pros Mentally strengths you, so if you find yourself in a POW camp at some point - it will seem like a vacation... Cons I'm going to provide you with a realistic review of working at Tris Pharma, complete with actual facts (you know, those little pieces of knowledge that Tris fails to admit exist - like a Trump tax return). I served out my 3 year sentence and was finally released for early when the brainwashing and verbal beatings just stopped working. I don't know that I can describe in words what it is like to work for Tris, I would say it is something that needs to be experienced, but that's like saying one needs to experience drowning or burning alive. Sometimes you just have to believe its going to be unpleasant. Reading the past reviews, it is clear that the company has paid to have the positives ones written or more in line with Tris policy - forced employees to come to work on a federal holiday and write them for free. I do agree with the most recent review. This brings me to my first fact - turnover. Can you think of any other company that has a 90% plus turnover in management? and I'm talking senior management. These are successful people that have moved up the ranks at prestigious companies, some multiple billion dollar global organizations. For some reason, they just can't seem to or want to stay employed at Tris. Just so you don't think I'm making this up, here is just a partial list of the people who have come and gone at Tris over the last few years: Chief Scientific Officer Director of Finance Director of Supply Chain VP of Operations (1) VP of Operations (2) VP of Operations (3) VP of Quality (1) VP of Quality (2) Chief Business Officer Manager of Operations (1) Manager of Operations (2) Manager of Operations (3) Director of Quality Assurance Sr Manager of Compliance Sr Manager of Quality Control Supervisor Quality Control Supervisor Quality Control (2) VP of R&D (1) VP of R&D (2) Director of Method Development VP of Regulatory Sr. Manager of Regulatory Manager of Regulatory Manager of Packaging At least 8 purchasing employees - in a total group size of 3 Director of product Development VP of Sales VP Business Develpment Director of IT Manager of IT More operators, scientists, chemists, quality inspectors than I could possibly count. Now this is not a comprehensive list, but I can assure you it is factual. Can you think of any other organization in the world that can turnover this number of management positions in 4 years and still be successful? Keep in mind the company only had 50 - 200 total people during this time. Of course you can't. It isn't possible and that's why Tris isn't successful anymore either. Fact #2 - Sure things at Tris were going well for a while and the owner made a ton of money (fact #3 - check out the $10 million condo he bought last year in Miami, all while telling the employees that there is no money for raises or bonuses (again). Fact #4 - Take a look at Tris' partner Vernallis' stock. Went from $25 to $18 because of the poor FDA inspection Tris just had and an FDA letter they received, where their product was not approved. This comes as no surprise when you have an owner that is just about getting product out the door rather than assuring it is quality product. Hence all the recent recalls. Fact #5, #6, #7 - We have all seen foreign companies like this before and they always get what's coming to them. Tris is at that point. Tris is now in trouble with the FDA, its partners are not happy with them and will start leaving. The sales forces can't seem to get anything done and how can they with the shoe string budget they are given. Hard to sell $200 a bottle pills when you have to take customers to Bob's Big Boy for dinner. The worse employees will remain, the good ones have left or will leave. Talk to others in the pharmaceutical industry, they all know Tris and the CEO. Its like a red badge of courage to have put your time in and learned what not to do and how not to run a company. Soon they will have only the most incompetent people remaining and that will be the final straw in this long drawn out tragedy.... RIP
weber77
20/10/2017
13:07
Well, they claim they cannot say anything about this because this issue is with Tris and as a private company Tris is not obliged to share any more information than it wants to, and further Tris itself operates on the basis of saying as little as possible.
romeike
17/10/2017
08:22
Still no information on how the issues raised by the fda are going to be dealt with.Not good enough!
fhmktg
13/10/2017
12:42
Not so sure about that the sell is barely above the buy, but yeah, they'll do well if there is a return to 40p. Going to take some significant good news though. The board promised to triple prescriptions on Txr over the last period, if it becomes clear early next year that that isn't likely to be the case then I really think it will be time for a new CEO and a review of strategy. At the moment the big problem is the cash burn vs revenue. Even if they were to get Moxatag, Txr, CCP-07 and CCP-08 all earning revenues, would it be enough to cover even half the current cash burn? Really I think they need to be earning at least 10 mil on Txr alone next period for their strategy to be viable.
romeike
12/10/2017
16:21
Probably a shorter bottom fishing. Did well whoever it was
bantam175
12/10/2017
12:46
Somebody has faith, everything that comes for sale gets mopped up.
fhmktg
12/10/2017
11:38
I suspect an institutional investor lost patience with board and is dumping stock. Cannot see any rationale for a currently well funded business to go to the market while its share price is in the gutter.
romeike
12/10/2017
11:37
If it is it would show massive incompetence on the part of the board. They have 65 million or so in the bank, why fund raise when share price is rock bottom. What can be so urgent they have to fund raise now when they recently said they have plenty of cash and no debt and were reasonably confident they wouldn't need to raise more.
romeike
12/10/2017
11:32
Looks.like.a fund raising coming judging by the lack of news and share price fall just like agl and nano . Expect it to level off jut above the issue price imo . So far looks like it could be at 8p or possibly 5p . Usual share price reaction when the company goes to the city asking for money no other real explanation I can see
bones698
12/10/2017
11:13
10p fund raising...........????????????
chrisdgb
09/10/2017
07:45
Is this worth buying? -priced almost like option money. Financially sound but massive cash burn. Any views from pharma expert?
meijiman
09/10/2017
07:30
Indeed, the big share holders need to get active with this one..........
chrisdgb
02/10/2017
14:22
Healthcare up across the board today with one exception - Vernalis. Time for a certain Mr. Woodford to insist on regime change at Vernalis?
romeike
28/9/2017
10:27
Is the incompetent CEO really considering a capital raise with the share price at rock bottom? Of course he is, he only cares about keeping his snout in the trough.
romeike
27/9/2017
11:32
brown envelopes all round for the directors and 'advisors' brown pants for the shareholders
pugg1ey
27/9/2017
11:02
SP here finding new lows as management fails to get to grips with major issues, fails to update shareholders with any good news and fails to revise its strategy. Why is Ian Garland still CEO?
romeike
17/9/2017
20:29
not quite sure what your point is hvs? was that suppose to be a dig at me? (best ignored judging by previous posts)
bountyhunter
16/9/2017
11:26
IDIOTS ABOUND and this is a bit too vague for my liking, again missing a target date other than sometime in 2018.. lol !!!!!! lol !!!!!!!!!!
hvs
12/9/2017
20:19
http://www.telegraph.co.uk/news/2017/09/12/nhs-fears-worst-flu-season-history/
romeike
12/9/2017
14:58
exactly, insufficient detail on this important matter given that Suir went into liquidation in May 2016 which is more than a year ago now
bountyhunter
12/9/2017
12:52
- the Company has progressed a new source of supply. Again this is all talking out the side of the mouth stuff. In all likelihood the company has not progressed anything other than negotiating with people who bought the old Suir assets (IQ Pharmatek) for them to continue to supply Moxatag under contract. The continuation of supply is not particularly interesting, what we want to know is what are the terms on which this drug is being supplied and will Vernalis actually make any significant margin on it. We await details but I would anticipate Vernalis is looking at a much reduced margin on this product.
romeike
12/9/2017
10:43
yes encouraging revenue increases but costs need to be reduced and should be some target dates on this bit imho... "We are also working closely with our partner Tris and the FDA to resubmit the NDAs for CCP-07 and CCP-08 as quickly as possible." and this is a bit too vague for my liking, again missing a target date other than sometime in 2018... "The previous manufacturer of Moxatag(R) , Suir, went into liquidation in May 2016. During the year, the Company has progressed a new source of supply and intends to manufacture Moxatag(R) in 2018."
bountyhunter
Chat Pages: 137  136  135  134  133  132  131  130  129  128  127  126  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20171118 23:43:35